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It is widely accepted that the brain responds to mechanical trauma and development of most neurodegenerative diseases with an
inﬂammatory sequelae that was once thought exclusive to systemic immunity. Mostly cationic peptides, such as the β-defensins,
originally assigned an antimicrobial function are now recognized as mediators of both innate and adaptive immunity. Herein
supporting evidence is presented for the hypothesis that neuropathological changes associated with chronic disease conditions of
the CNS involve abnormal expression and regulatory function of speciﬁc antimicrobial peptides. It is also proposed that these
alterations exacerbate proinﬂammatory conditions within the brain that ultimately potentiate the neurodegenerative process.
1.Introduction
Chronic activation and impaired regulation of the innate
immune response within the brain has been proposed by
Fern´ andez et al. [1] as a primary, unifying cause of Alz-
heimer’s disease (AD) [2]. Antimicrobial peptides (AMPs)
are important components of the innate immune system
and also have been shown to function as regulators of the
adaptive immune system [3, 4]. Williams [5] proposed that
these agents may underlie neuropathologies within the
human brain associated with neurodegenerative disease, ag-
ing, diabetes mellitus, and traumatic brain injury (TBI)
[6]. The most extensively studied AMPs are the human
β-defensins (hBDs), and the cathelicidin LL37/hCAP18,
the principal candidate immunoregulators in extracerebral
tissues [7, 8]. Herein, we present the hypothesis, based
primarily on ﬁndings from extracerebral tissues, that AMPs
also play a functional role in the human brain [9, 10].
Although speculative, we hope that this postulate will
contribute to expanding future research into AMP function
within the brain.
A proinﬂammatory state within the brain is a known
consequence of TBI [11], neurodegenerative disease in-
cluding Alzheimer’s disease (AD) [12], senescence [13], and
diabetes mellitus [14]. Despite intense research, neuroin-
ﬂammatory-associated mechanisms that may underlie neu-
ronal injury remain poorly understood. The human β-
defensin peptides hBD-1 and hBD-2 have been isolated,
and two genes encoding homologous β-defensin-1 and -2
(rBD-1 and rBD-2) have been identiﬁed in the rat [15].
The presence of LL37 in serum and cerebrospinal ﬂuid
extracted from patients with bacterial meningitis has also
been reported. This peptide has been localized in astrocytes
and microglial cells in a pneumococcal meningitis rat model
[16]. β-defensins have been hypothesized to play a role in
the etiology of neurodegeneration with a focus on traumatic
brain injury, a risk factor for AD [17]. Moderate-to-severe
TBI induces neuropathological responses that are similar to2 The Scientiﬁc World Journal
changes described in the AD brain, including development
of chronic inﬂammation and hyperglycemia [18–22].
2. HypothesizedRole of β-Defensin
Antimicrobial Peptides in Proinﬂammatory
Mechanisms of Neurodegeneration
The β-defensins-1, -2, and -3 are recognized as principal
regulators of immune response and inﬂammation [23–25].
Here, we propose that central to impairment of the innate
and adaptive immune response, and thus prolongation of
inﬂammation within the brain, is a dysregulation of speciﬁc
AMP function, including constitutive and inducible β-
defensin peptides (Figure 1) .A t t e n u a t i o ni nf u n c t i o nm a y
be attributed to an ap r i o r idevelopment of an insidious
condition, such as hyperglycemia and/or increased insulin
resistance, a component of many neuropathological condi-
tions including AD [26], Huntington’s disease [27], aging
of the brain [28], diabetes mellitus [29, 30], and TBI [31].
Reduced expression of hBD-2 and -3 mRNA occurs in vitro
subsequent to exposure of human primary epithelial cells
to high glucose (30mM) and/or low insulin (<5μg/mL)
(Williams, unpublished). These ﬁndings are consistent with
the hypothesis that dysregulated expression of constitutively
expressed AMPs like hBD-1 [32], speciﬁc inducible hBDs,
including hBD-2 and-3, and perhaps other AMPs such as
LL-37 [33], all potential modulators of inﬂammation, may
occur in the traumatized brain and in brain tissue exhibiting
chronic inﬂammation-associated neurodegeneration, as is
observed in AD. Conversely, abnormally high levels of AMPs
could also contribute to elevated and prolonged inﬂamma-
tionwithinsusceptiblebrainregions.Chronichyperglycemia
could potentially contribute to glycation (see Figure 1)o f
speciﬁc amino acid residues on AMPs with formation of
advanced glycation end-products (AGEs), conformational
change, and ultimately inhibition of or prolongation of AMP
function [34]. The intensity of a proinﬂammatory process
subsequent to altered AMP expression level and/or function
most likely would reﬂect the combined eﬀects of multiple
factors including the level of inﬂammatory cell activation,
inﬂammatory cell density and rate of cell turnover, and
eﬀectiveness of compensatory anti-inﬂammatory modula-
tors such as microglial intervention and upregulation of
the anti-inﬂammatory cytokine IL-10 [35]. Thus, the induc-
tion of inﬂammation within susceptible brain regions of
chronic diabetics presenting with poor glycemic control
(hyperglycemic) and in chronic neurodegenerative diseases
may exhibit chronic, but low-grade inﬂammation [36, 37]
that may not be substantially greater than that observed in
more acute models of inﬂammation.
3.MildTBIandMoreSevere
HeadTraumaInduceCellularInjuryand
anInﬂammatoryResponse inthe Brain
Neuropathological alterations in neurons are sustained not
only in moderate and severe TBI, but also in mild TBI,
as indicated by metabolic depression indicative of neuronal
injury [38], and other metabolic abnormalities [39–41].
Immune response and inﬂammation are considered primary
to the progression of closed head injury, yet underlying
mechanisms are not well understood. It is now recognized
that immune function and immunomodulatory capacity are
not limited to those cells classically deﬁned as “immune”
cells; so-called “nonimmune” cells also are critical to the
immune response. In the brain, astrocytes, epithelium of the
choroid plexus, and meningothelial cells express and likely
secrete immunomodulatory antimicrobial peptides, in-
cluding hBDs-1 and -2, that could inﬂuence inﬂammation
within the brain [9, 42]. Astrocytes, for instance, are capable
of responding to bacterial pathogens, including Staphylococ-
cus aureus [43]. The responsiveness of these cells may be
region speciﬁc, as is the case with regional responsiveness
to lipopolysaccharide (LPS), and basal proﬁle of induced
cytokine expression [44–46]. Thus, astrocytes, although not
immune cells according to classical deﬁnition, may signiﬁ-
cantlyaﬀectcentralnervoussystem(CNS)immuneresponse
in the pathological state, not only by variable expression and
release of proinﬂammatory cytokines such as IL-1β, but also
by expression of immunomodulating AMPs [47–50].
Because of the dynamic nature of the response and
the complexity of functional interrelationships between ex-
pressed immunomodulators, the role that the innate im-
muneresponseandinﬂammationplayinneuropathologyre-
mains ill-deﬁned. Some components of the immune re-
sponse, including cell-mediated immunity concurrent with
reduced levels of key immunoregulatory cytokines, may be
suppressed leading to exacerbated inﬂammation following
severe head injury [51], and perhaps in neurodegenerative
diseases in general. Still unclear is how the immune response
contributes to secondary brain injury following TBI, and
to what extent components of the response mediate not
only neuronal, but also astrocytic damage. Although speciﬁc
cytokines may be expressed at reduced levels following TBI,
the development of secondary and tertiary changes in brain
cell function can be accompanied by increased expression
of proinﬂammatory cytokines. For example, upregulation
of interleukin-1 (IL-1α and β) and tumor necrosis factor
(TNF)-α, both components of the chronic inﬂammatory
response, occurs with onset of depression [52, 53]a n d
headache [54]; both are frequently described as late clinical
sequelae of TBI.
TBI induces a cell-mediated immune response within
the brain and systemic circulation [55]. Under physiological
conditions, the blood-brain barrier (BBB) limits movement
of immunocompetent cells into the brain thus regulating
theimmunologicalresponse[56].TBI-induceddisruptionof
the BBB can lead to unregulated translocation of leukocytes,
includingmonocytes,intotheaﬀectedbrainregionwithsub-
sequent activation of microglia and astrocytes [57], con-
comitant with elevated expression of proinﬂammatory
cytokines [58, 59]. However, both astrocytes and microglia
also can limit or actively suppress inﬂammation by the
secretion of anti-inﬂammatory factors such as IL-10, thereby
aﬀecting the immunosuppressive response with neuropro-
tective consequences [48, 60, 61].The Scientiﬁc World Journal 3
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Figure 1: It is hypothesized that reduction or abnormal elevation of AMP expression by brain microglia, astrocytes, or choroid plexus
epithelium (CP) may contribute to loss of AMP-induced regulation of dendritic cell maturation and activity. Prolonged and elevated
dendritic cell activity could in turn contribute to chronic release of proinﬂammatory cytokines (IL-6, IL-8, etc.) that ultimately promote
neuronal cell injury and death. Hyperglycemia-induced glycation of speciﬁc AMPs may inhibit antimicrobial and immunomodulatory
function.
4. TBI-Induced Hyperglycemia
ExacerbatesCellularDamage and
Inﬂammation in the CNS
Acute hyperglycemia is a component of the normal stress
response and can exacerbate brain injury by promoting
oxidative stress [62] with potentiation of the inﬂammatory
response [63–65]. Overall, neurological outcome worsens
after trauma or stroke when glucose levels are even acutely
elevated [66, 67]. Acute hyperglycemia with a serum glucose
level of ≥170mg/dL is associated with poor outcome in head
trauma patients who present with a Glasgow Coma Scale
(GCS) of 8 or lower [68].
Elevated serum glucose can occur in mild concussive
head trauma in humans [69] and in mild, moderate, and se-
vereheadtraumainrats[70].Moreover,extracellularglucose
is signiﬁcantly increased in the hippocampus and cerebral
cortex ipsilateral to the site of ﬂuid-percussion injury in the
rat [71].
Acute onset of hyperglycemia (within 1 hour of injury)
contributes to cerebral neuropathology [72]. The pres-
ence of even mild-to-moderate serum glucose elevation
(≥150mg/dL) is detrimental to vulnerable brain regions
[73], such as the cerebral cortex and hippocampus [74,
75]. These regions mediate self-regulation, emotion, social
functioning, and working memory, all cognitive functions
adversely aﬀected by TBI [76]. Neurons and astrocytes are
both susceptible to hyperglycemia-induced injury [77, 78].
5. β-DefensinsAreMediators
of the InnateImmuneResponse and
Modulate Inﬂammation
The defensin family of immunomodulatory peptides is an
evolutionarily conserved group of cationic peptides that
contribute to innate host defense. Constitutively expressed
hBD-1 and inducible hBD-2 and -3 are expressed by epithe-
lium and epithelial-derived cells [79–83]. All three hBDs
can induce cellular expression of cytokines and chemokines;
however, hBD-2 and -3 are particularly important mediators
of cytokine release, including release of IL-6, MIP-3α,M C P -
1, and RANTES through activation of the G protein and
phospholipase C-dependent pathways [84]. These hBDs and
LL-37 also promote epithelial cell migration and prolifera-
tion, angiogenesis, chemotaxis, and wound repair [84, 85].
Recruitment of speciﬁc cells such as immature dendritic cells
and memory T cells involves the binding to or modulation
of the chemokine receptor CCR6 by hBDs-1, -2, or -3 [86–
88]. Some hBDs can also interact with other chemokine
receptors, including CCR2 [89] and the G protein-coupled
receptor CXCR4 [4]. These same receptors are also expressed
by the immunocompetent astrocytes and microglia of the
human brain [90, 91]. The hBDs-1 and -2 can be expressed
by astrocytes and microglia of both human [9] and rat brains
[92, 93]. The capacity of resident astrocytes and microglia to
express hBD-1 is consistent with our hypothesis that hBDs,
through their ability to activate immune cells and modulate
cytokinerelease[84,94],mayfunctiontoregulateinﬂamma-
tion within the brain. Tiszlavicz and colleagues have recently
demonstrated the expression of hBD-2 mRNA and synthesis
of hBD-2 protein in human brain capillary endothelium
following in vitro exposure to Chlamydophila pneumoniae
[95]. Therefore, the immunoregulatory function of the β-
defensins may be established by the microenvironment and
stimulus experienced by the cell expressing the peptide. Sev-
eral lines of evidence support both a pro- and anti-inﬂam-
matory role for some antimicrobial peptides. These peptides,
including hBD-2, and cathelicidin LL-37 may promote
the release of both proinﬂammatory (IL-6, IL-18) and
anti-inﬂammatory (IL-10) cytokines and chemokines from4 The Scientiﬁc World Journal
epithelial cells as shown by several in vitro studies [84, 96].
Donnarumma et al. [97] also have shown in the human
lung cell line A549 that hBD-2 alone or in combination with
moxiﬂoxacin can reduce the expression of IL-1β.O v e r e x -
pression of rat β-defensin-2 (rBD-2) in the lungs of Sprague
DawleyratschallengedwithP. aeruginosa resultsinreduction
of pulmonary inﬂammation [98]. If the in vitro ﬁndings
presented above accurately reﬂect antimicrobial function in
vivo, then a dysregulation of cerebral expression of speciﬁc
antimicrobial peptides may favor either exacerbation or
amelioration of the inﬂammatory response within the brain
depending upon which extracellular conditions predomi-
nate. With respect to the β-defensins, we propose that hBD-
1 and -2 can contribute to either a pro- or anti-inﬂam-
matory modulation of the neuroimmune response with de-
pendenceuponthetemporalcellularexpressionofrespective
cytokines and chemokines. The normal expression proﬁle,
and therefore function of speciﬁc hBDs, may be compro-
mised when the brain is subjected to mechanical trauma
or disease. For example, the level of constitutively expressed
hBD-1 is selectively upregulated in diﬀerentiating, but not
proliferating, keratinocytes [99].
Brain trauma is followed by onset of the acute phase
stress response and development of acute hypermetabolism
within the brain [100]. With moderate-to-severe TBI, in-
creasing insulin resistance leads to a delayed but chronic
hypometabolic state that promotes extracellular hyper-
glycemia [31]. An in vitro study of human embryonic kidney
(HEK) cells by Barnea et al. [101] has shown that increasing
intracellular glucose availability increases the expression of
hBD-1. However, in rodent models of diabetes mellitus type
II, hBD level, including that of hBD-1, was low compared
to nondiabetic controls. This apparent discrepancy could be
corrected by treatment of animals with insulin [102]. Both
diabetes and TBI lead to increased insulin resistance and
extracellular hyperglycemia. Insulin is required by astrocytes
for proper metabolic function [103, 104]. Therefore, brain
regions susceptible to the development of hyperglycemia
and insulin resistance might aﬀect the inﬂammatory state
of the involved tissues by modulating expression of AMDs,
including β-defensin peptides.
6. β-DefensinsAreExpressedin
Astrocytes,Microglia,andinEpithelium
of the Choroid Plexus
TBI leads to activation of astrocytes and microglia as part
of the innate immune response [105]. Astrocytes are strate-
gically sited to provide early defense and modulatory control
of cellular events following cerebral insult. The gene chip
analysis by Falsig et al. [106]i so fp a r t i c u l a ri n t e r e s ta s
it shows that a number of genes expressed in murine
astrocytes are linked to antiviral/antimicrobial defense and
are coordinately regulated. The analysis did not assess either
β-defensins or the cathelicidin LL37. Nevertheless, these
ﬁndings, together with the reported induction of hBD-2
in human astrocytes by cytokines [9], are consistent with
the hypothesis that hBD-2 might function as an initial
line of defense within the CNS either as an antimicrobial,
immunomodulator, or both. Astrocytes, microglia, and the
choroid plexus constitutively express hBD-1 [42], again
suggesting that hBDs could play a role in the innate immune
response of the traumatized brain.
Currently, there are no reported studies on hBD expres-
sion or function within the human brain. Hyperglycemia
[70], concomitant with increased insulin resistance, is an
early feature of TBI in the acute phase response to trauma
[107]. It is noteworthy that the level of trauma needs not be
severe to elicit a marked elevation in cortical glucose within
24 hours [108] ,a n de v e nm i l dh y p e r g l y c e m i ac a na d v e r s e l y
aﬀectbrainfunction[109].Althoughhyperglycemiaremains
a primary focus of many studies, insulin resistance might
also contribute signiﬁcantly to cellular dysfunction following
trauma. Insulin receptors are widely distributed within the
brainwiththeirhighestdensitiesincerebralcortex,hypotha-
lamus, and hippocampus [110]. Because glucose incorpo-
ration into astrocytes is insulin sensitive [111], astrocytes
could be particularly prone to trauma-induced dysfunction
although some signaling pathways associated with hip-
pocampal neurons also are insulin dependent [112, 113].
Acute hyperglycemia and insulin resistance can result in
alteration of the immune response in favor of a proinﬂam-
matory condition leading to more extensive or prolonged
inﬂammation [64].
7. β-DefensinsMayBeNeuroprotectivethrough
Their Ability to Impede Cellular Apoptosis,
Increase Cellular Proliferation, and Promote
CNS WoundHealing
Apoptosis contributes to delayed neuronal cell death in TBI
[114]. Mild TBI in the lateral ﬂuid percussion rat model
has induced apoptotic TUNEL(+) astrocytes and neurons
in both grey matter of the cortex and in underlying white
matter [115, 116]. There is evidence that β-defensins in
vitro can attenuate the onset of proapoptotic mechanisms in
human neutrophils where hBD-3 can reduce apoptosis via
the chemokine receptor CCR6 [117].
TBI may increase apoptosis and also enhance reac-
tive astrocytosis [118]. Of importance is the observation
that ablation of proliferating reactive astrocytes with the
antiviral agent ganciclovir signiﬁcantly increases neuronal
degeneration and the inﬂammatory state [119]. Studies in
vivo indicate that chronic activation of the innate immune
response can induce neuronal injury [120–122], perhaps
through activation of the inﬂammasome complex [123].
Thus, modulation of this response, perhaps by speciﬁc hBDs
and/or other immunomodulatory antimicrobial peptides,
could be critical to the maintenance of neuronal health.
Moreover, the potential contribution of β-defensins to
reparation of inﬂammation-induced cellular injury in the
CNS is illustrated by the ability of hBD-2 to stimulate
proangiogenic activity, as demonstrated in human umbilical
vein endothelial cells despite absence of growth factors such
as VEGF [23]. These observations in vitro, although limited
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within the CNS, are nevertheless consistent with a proposed
function for hBD-2 within the brain that is supported by
the inducible expression of this peptide in human astrocytes
stimulated by the proinﬂammatory cytokines IL-1β and
TNF-α [9].
8.DendriticCellsAreCriticalModulators
oftheInnateandAdaptiveImmuneResponse
Dendritic cells (DCs) are antigen-presenting cells (APCs)
crucial to pathogen recognition and regulation of the
inﬂammatory response. DCs are critical to the induction
and regulation of adaptive immunity through their release of
cytokines, and subsequent activation of lymphocytes, polar-
ization of T-helper type 1 (Th1) CD4+ cells, development
of cytolytic T cells, and expansion of the antibody response
to antigen [124, 125]. Upregulation of toll-like receptors
(TLRs) by pathogen-associated molecular patterns (PAMPs)
can induce maturation of DC to an inﬂammatory phenotype
that upregulates the adaptive immune response [126]. Under
physiological conditions, dendritic cells are restricted to
the meninges and choroid plexus of the brain and are
not normally present within the brain parenchyma [127].
However, rapid accumulation of DCs proximal to the site
of brain inﬂammation occurs with neurodegeneration [128],
including AD [129], autoimmune disease, bacterial and viral
infection, and brain trauma [128, 130, 131]. Recent studies
suggest that DCs exhibit a regulatory function with regard to
the neuroinﬂammatory process [132] and can express both
pro- and anti-inﬂammatory cytokines [133]. In this regard,
maintenance of an active DC population may contribute to
prolongation of the inﬂammatory process [134–136]w i t h
progressive neurodegeneration.
9. β-Defensin Peptides May ModulateBoth
InnateandAdaptiveImmune Responses
withinthe Brainthrough Chemotaxis and
Promotion of DendriticCell Maturation
The antimicrobial function of AMPs might actually be
secondary to their immunomodulatory capabilities [137].
One mechanism by which the initial innate response can
activate an adaptive response is through chemoattraction,
maturation, and activation of dendritic cells [138]. At least
some AMPs, including β-defensins-1, -2, and -3, and LL-
37 can chemoattract immature dendritic cells and induce
their maturation [139–142]. Yang et al. [86] have shown
that human β-defensin-2 is chemotactic for immature DCs
through binding to the DC-expressed CCR6 receptor.
10.β-Defensin Peptides May Limit
Inﬂammation through Anti-Inﬂammatory
Pathways and by Induction of Dendritic
CellDeath
The ability of speciﬁc β-defensin peptides to regulate in-
ﬂammation may rely not only on promotion of adaptive
immunity and inﬂammation, but also on curtailing the
inﬂammatory process itself. Chronic inﬂammation is coun-
terproductive, often contributing to excessive cell death, and
compromising tissue repair. Hao et al. [143]h a v ed e m o n -
strated improved wound healing in cultured bone-marrow-
derived mesenchymal cells (BMSCs) expressing both human
platelet-derived growth factor-A (hPDGF-A) and hBD-2.
Pingel et al. [144] also show that hBD-3 can attenuate
the proinﬂammatory cytokine response to microbial anti-
gens by myeloid dendritic cells exposed to recombinant
hemagglutinin B (rHagB), one of ﬁve hemagglutinins that
promote binding of Porphyromonas gingivalis (P. gingivalis)
to host cells, including myeloid DCs. The mechanism by
whichhBD-3attenuatestheIL-6,IL-10,andTNF-αresponse
in human myeloid dendritic cells was not determined.
However, Pingel et al. demonstrated strong binding between
the highly cationic hBD-3 and immobilized rHagB. Further-
more, signiﬁcantly lower levels of ERK 1/2, but not JNK 1/2
or p38, were observed, suggesting a partial involvement of
the MAPK pathways, important to control the inﬂammatory
response to P. gingivalis. The authors propose that binding
of hBD-3 to rHagB may be an initial step leading to
suppression of select proinﬂammatory cytokine pathways
in human myeloid dendritic cells. Recently, Semple et al.
[145] demonstrated that hBD-3 attenuates transcription of
proinﬂammatory genes in TLR4-stimulated macrophages.
Whether these results are relevant to defensin function
within the brain is unknown. Such a functional versatility on
the part of speciﬁc defensins would be highly advantageous
tocontrolledmodulation oftheimmune response withinthe
CNS.
β-defensins might also modulate the duration of inﬂam-
mation by controlling the viability of activated macrophages
and the same dendritic cells that they chemoattract and
induce to maturity. In an interesting study of TLR-4-de-
pendent maturation of immature DCs by murine β-
defensin-2 (mBD-2), Biragyn et al. demonstrated that fol-
lowing activation of DCs, mBD-2, not orthologous to any
known hBDs, induces DC death via an NFκB-dependent
induction of TNF-α and TNF receptor 2 (TNFR2) expres-
sion on the APC surface [146]. Cytotoxicity was shown to
be due to a defensin-induced signaling cascade that requires
TNFR2 and not mBD-2 directly. Additional experiments
by this group clearly showed that these observations were
not restricted to murine β-defensin, since hBD-3 also was
capable of inducing, ﬁrst, DC maturation and then death
s e v e r a ld a y sl a t e r .
The studies noted above strongly suggest that at least
some hBDs, under certain conditions, possess an anti-
inﬂammatory or inﬂammation-limiting capability. Condi-
tions under which these defensin-related anti-inﬂammatory
mechanisms are activated in vivo and whether they function
within the CNS remain to be determined. The pro- or
anti-inﬂammatory nature of hBDs may depend largely on
temporal regulation of cellular events, including number
and type of inﬂammatory cells (microglial activation state)
and molecular expression and inactivation of pro- or anti-
inﬂammatorycytokinesandchemokinesbyimmunocompe-
tent cells within the cellular microenvironment.6 The Scientiﬁc World Journal
11. Summary andConcluding Remarks
A number of neurodegenerative diseases, including AD, the
aging process, TBI, and type II diabetes mellitus, exhibit
similar pathogenic cascades. Hyperglycemia and elevated
insulin resistance are common sequalae, among others, that
may underlie cellular dysfunction within the brain involving
altered expression of immunomodulatory peptides, such as
the β-defensins. We propose, based on studies that support
a central role for β-defensins as modulators of immune re-
sponse and inﬂammation in extracerebral tissues, that these
peptides,andperhapsotherAMPsendogenoustothehuman
brain, contribute to regulation of the immune response
and inﬂammation within the CNS. This would likely
occur in part through the ability of speciﬁc antimicrobial
peptides, such as β-defensins-1, -2, and -3, to regulate
dendritic cell function and viability. We also propose that
neuropathological development of hyperglycemia, and/or
insulin resistance, attenuates β-defensin function through
reduced cellular expression of the peptide and compromised
ability to modulate the neuroimmune response, perhaps
through uncontrolled dendritic cell activation. However,
AMP function is unlikely to be inﬂuenced by a single mech-
anism. Given the complex etiology of neurodegenerative
diseases, it is likely that peptide activity is a function of
multiple factors inherent within speciﬁc regions of the brain.
TheneteﬀectonAMPfunctionmaybereﬂectedinincreased
pro- or anti-inﬂammatory activity by the AMP peptide(s)
that results in an intensiﬁed or prolonged inﬂammatory
process. The recent study by Soscia et al. [147], for example,
suggests that the oligomerized form of β-amyloid 1–42 (Aβ),
an anionic peptide associated with AD neuropathology, may
function as a proinﬂammatory antimicrobial peptide in
regions of the brain exhibiting elevated levels of the pep-
tide. Oligomerization of monomeric hBD-2 also has been
demonstrated and is likely to occur with other hBDs and
AMPs [148]. Many AMPs exhibit structural characteristics,
including a β-sheet conformation similar to Aβ(1–42) that
contributetooligomerization.YetwhilesomeAMPslikefrog
skin dermaseptin S9 form amyloid-like ﬁbrils [149], others
such as hBD-2 and -3 do not [150]. Interestingly, as noted
by these studies, amyloidogenic properties may adversely
aﬀect normal peptide function and favor a proinﬂammatory
state, while nonamyloidogenic oligomerization appears to
promote antimicrobial function, including that of the β-
defensins without promoting inﬂammation. Increased or
decreased β-defensin expression and function could con-
tribute signiﬁcantly to chronic inﬂammation and ultimately
to the neurodegenerative process itself. Clearly, regulation of
the innate immune response in tandem with upregulation
of cellular repair processes within the CNS is complex and
highly integrated with considerable redundancy. Neverthe-
less, the proposal that AMPs function within the brain
is supported by the cytokine-induced expression of AMPs
by human astrocytes and microglial and the functional
activity of AMPs in multiple organ systems, as described
above. Whether speciﬁc AMPs play a central role in the
onset or promotion of the neuroinﬂammatory process and
neurodegeneration is currently unknown, emphasizing the
importance of further investigation into the regulatory
mechanisms that control innate and adaptive immunity
within the CNS.
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